Abstract 1514P
Background
At interim analysis (IA) of RATIONALE-306 (NCT03783442), 1L TIS + chemo demonstrated a statistically significant, clinically meaningful improvement in overall survival (OS) vs PBO + chemo, with a manageable safety profile, in patients (pts) with advanced/metastatic ESCC. Here, we report updated efficacy and safety data with minimum (min) 2 years’ follow-up.
Methods
Adults with unresectable locally advanced recurrent/metastatic ESCC and no prior systemic treatment for advanced disease were enrolled and randomized (1:1; stratified by region, prior definitive therapy, and investigator [INV]-chosen chemo) to receive TIS 200 mg (Arm A) or PBO (Arm B) IV Q3W + chemo (platinum + fluoropyrimidine or platinum + paclitaxel), until disease progression, intolerable toxicity, or withdrawal. The primary endpoint was OS in the intent-to-treat population. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), duration of response (DoR) per INV, and safety.
Results
649 pts were randomized (Arm A n=326, Arm B n=323). At data cutoff (Dec 31, 2022), min study follow-up was 25.2 months; improvements in OS, PFS, ORR, and DoR in Arm A vs B (Table) were maintained relative to the IA. Similar to the IA, incidences of any-grade (96.6% vs 96.3%) or ≥grade 3 (66.7% vs 64.5%) treatment-related adverse events (TRAEs) were comparable between Arms A and B, respectively; treatment-emergent adverse events leading to treatment discontinuation were higher in Arm A (31.8%) vs B (22.1%). In Arm A vs B, respectively, serious TRAEs occurred in 29.3% vs 19.6% of pts; TRAEs leading to death occurred in 1.9% and 1.2%.
Table: 1514P
Arm A: TIS + chemo (n=326) | Arm B: PBO + chemo (n=323) | |
mOS, mo (95% CI) HR (95% CI) | 17.2 (15.8, 20.1) | 10.6 (9.3, 12.1) |
0.67 (0.56, 0.80) | ||
24-mo OS, % (95% CI) | 37.9 (32.5, 43.2) | 25.0 (20.2, 30.0) |
mPFS, mo (95% CI) a HR (95% CI) | 7.3 (6.9, 8.3) | 5.6 (4.9, 6.0) |
0.61 (0.51, 0.73) | ||
24-mo PFS, % (95% CI) | 18.1 (13.6, 23.1) | 7.2 (4.4, 11.0) |
ORR, % (95% CI) a | 63.5 (58.0, 68.7) | 42.4 (37.0, 48.0) |
mDoR, mo (95% CI) a | 7.1 (6.1, 8.1) | 5.7 (4.4, 7.1) |
24-mo DoR, % (95% CI) | 19.6 (13.9, 25.9) | 10.1 (5.0, 17.1) |
aPer INV. CI, confidence interval; HR, hazard ratio; m, median; mo, months. |
Conclusions
After min 2 years’ follow-up, 1L TIS + chemo continued to demonstrate clinically meaningful improvements in OS and PFS and durable tumour response benefit vs PBO + chemo in pts with advanced/metastatic ESCC, with no new safety signals.
Clinical trial identification
NCT03783442.
Editorial acknowledgement
Medical writing support, under the direction of the authors, was provided by Adeline Lum Nde, PhD, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
R. Hubner: Financial Interests, Invited Speaker: Eisai; Financial Interests, Advisory Board: BeiGene; Financial Interests, Advisory Role: Novartis, Ipsen. K. Kato: Financial Interests, Speaker’s Bureau: Ono, BMS, MSD; Financial Interests, Research Grant: ONO; Financial Interests, Principal Investigator: BMS, Ono, MSD, Bayer, BeiGene, AstraZeneca; Financial Interests, Advisory Role: BMS, Ono, MSD, Bayer, BeiGene, AstraZeneca, Seagen, Servier. T. Kojima: Financial Interests, Invited Speaker: MSD, Bristol Myers Squibb, Ono Pharmaceutical; Financial Interests, Advisory Board: Boehringer Ingelheim, Kyowa Kirin, Taiho Pharmaceutical; Financial Interests, Research Grant: AstraZeneca, BeiGene, MSD, Amgen, Chugai Pharmaceutical, Taiho Pharmaceutical, Shionogi Pharma, Amgen Astellas BioPharma. L.S. Wyrwicz: Financial Interests, Personal, Advisory Board: BMS, Servier; Financial Interests, Personal and Institutional, Invited Speaker: BMS, MSD, Servier, BeiGene, Roche, AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca. H. Wu: Financial Interests, Full or part-time Employment: BeiGene; Financial Interests, Stocks/Shares: BeiGene. Y. Peng: Financial Interests, Full or part-time Employment: BeiGene. L. Wang: Other, Full or part-time Employment, Full time employment: BeiGene. L. Li: Financial Interests, Full or part-time Employment: BeiGene; Financial Interests, Stocks/Shares: BeiGene; Financial Interests, Training: BeiGene. H.H. Yoon: Financial Interests, Institutional, Invited Speaker: BeiGene; Non-Financial Interests, Writing Engagement: BeiGene; Financial Interests, Personal, Expert Testimony: MJH Life Sciences; Financial Interests, Institutional, Advisory Board: ALX Oncology, AstraZeneca, BeiGene, Bristol Myers Squibb, Macrogenics, Merck, OncXerna, Zymeworks, Novartis, Astellas, Amgen, Elevation Oncology; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, CARsgen Therapeutics, Merck, BeiGene; Financial Interests, Institutional, Other, Support for travel: BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21
1553P - Blood-borne assessment of stromal activation in esophageal adenocarcinoma to guide tocilizumab therapy: A randomized phase II proof-of-concept study
Presenter: Benthe Doeve
Session: Poster session 21